The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure

Not Applicable

Completed

• Conditions: Hyperuricemia; Chronic Kidney Disease
• Interventions: Drug: allopurinol

• Registration Number: NCT00978653
• Lead Sponsor: Istanbul University

Brief Summary

In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on endothelial dysfunction in patients with chronic kidney disease.

Detailed Description

Endothelial dysfunction (ED) is a key event in the development of atherosclerotic cardiovascular disease observed in patients with chronic kidney disease (CKD). Experimental models have shown that hyperuricemia causes hypertension and renin angiotensin system activation. In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on ED in patients with CKD.

Study Timeline

• Study Start: 2008-04
• Primary Completion: 2009-03
• Study Completion: 2009-05
• Status Verified: 2009-09
• Study First Submitted: 2009-09-14
• Study First Submitted QC: 2009-09-16
• Study First Posted: 2009-09-17
• Last Update Submitted: 2009-09-21
• Last Update Posted: 2009-09-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Laboratory finding of hyperuricemia
• Patients between ages of 18 and 60 years
• Non-diabetic patients
• Creatinine clearance values between 20 and 60 mL/min/1.73 m2

Exclusion Criteria

• Low (< 20 ml/min/1.73 m2) creatinine clearance,
• Patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome, congestive heart failure (CHF) (New York Heart Association class II or greater), valvular heart disease and a history of cerebral infarction or transient ischemic attack.
• Patients taking urate lowering medication (allopurinol and probenecid)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Allopurinol	allopurinol	Hyperuricemic (uric acid (UA)\>7 mg/dL), nondiabetic CKD patients without any comorbidity, age\<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.

Primary Outcome Measures

Name	Time	Method
Endothelial function improvement with uric acid lowering treatment	1 year

Trial Locations

Locations (1)

Istanbul Faculty of Medicine; 🇹🇷 Istanbul, Turkey